Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP | Globalization and Health BioMed Central Research Benefits of global partnerships to facilitate access to medicines in developing countries a multi-country analysis of patients and patient outcomes in GIPAP Panos Kanavos 1 Sotiris Vandoros1 and Pat Garcia-Gonzalez2 Open Access Address 1LSE Health The London School of Economics and Political Science London UK and 2The Max Foundation Seattle USA Email Panos Kanavos - Sotiris Vandoros - Pat Garcia- Gonzalez - Corresponding author Published 31 December 2009 Received 4 December 2008 m Accepted 31 December 2009 Globalization and Health 2009 5 19 doi l744-8603-5-l9 This article is available from http content 5 l l9 2009 Kanavos et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Access to medicines in developing countries continues to be a significant problem due to lack of insurance and lack of affordability. Chronic Myeloid Leukemia CML a rare disease can be treated effectively but the pharmaceutical treatment available imatinib is costly and unaffordable by most patients. GIPAP is a programme set up between a manufacturer and an NGO to provide free treatment to eligible CML patients in 80 countries worldwide. Objectives To discuss the socio-economic and demographic characteristics of patients participating in GIPAP to research the impact GIPAP is having on health outcomes survival of assistance-eligible CML patients and to discuss the determinants of such outcomes and whether there are any variations according to socio-economic demographic or geographical criteria. Methods Data for 13 568 patients across 15 countries available quarterly
